User profiles for T. Krahn
Timothy KrahnResearch Associate, Novel Tech Ethics, Faculty of Medicine, Dalhousie University Verified email at dal.ca Cited by 658 |
[HTML][HTML] ctDNA and CTCs in liquid biopsy–current status and where we need to progress
…, S Bender, T Krahn, T Schlange - Computational and …, 2018 - Elsevier
We discuss the current status of liquid biopsy and its advantages and challenges with a focus
on pre-analytical sample handling, technologies and workflows. The potential of circulating …
on pre-analytical sample handling, technologies and workflows. The potential of circulating …
[HTML][HTML] Circulating tumor cell PD-L1 expression as biomarker for therapeutic efficacy of immune checkpoint inhibition in NSCLC
V Kloten, R Lampignano, T Krahn, T Schlange - Cells, 2019 - mdpi.com
Over the last decade, the immune checkpoint blockade targeting the programmed death
protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis has improved progression-free and …
protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis has improved progression-free and …
[HTML][HTML] Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition
…, I Tinhofer, M Drosch, L Röse, TM Zollner, T Krahn… - BMC cancer, 2012 - Springer
… The blot was washed three times with PBS-T. Next, horseradish peroxidase-conjugated …
After three washing steps with PBS-T, detection was carried out using Amersham ECL …
After three washing steps with PBS-T, detection was carried out using Amersham ECL …
Cardioprotection by Ecto-5′-Nucleotidase (CD73) and A2B Adenosine Receptors
T Eckle, T Krahn, A Grenz, D Köhler, M Mittelbronn… - Circulation, 2007 - Am Heart Assoc
… Data were compared by 2-factor ANOVA or Student t test where appropriate. Values are
expressed as mean±SD from 4 to 6 animals per condition. For analysis of changes in transcript, …
expressed as mean±SD from 4 to 6 animals per condition. For analysis of changes in transcript, …
Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology
A Petraina, C Nogales, T Krahn, H Mucke… - Cardiovascular …, 2022 - academic.oup.com
Mechanism-based therapy centred on the molecular understanding of disease-causing
pathways in a given patient is still the exception rather than the rule in medicine, even in …
pathways in a given patient is still the exception rather than the rule in medicine, even in …
Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients
…, A Stresemann, T Krahn, T Henze… - Proceedings of the …, 2013 - National Acad Sciences
Circulating tumor cells (CTCs) are promising biomarkers for diagnosis and therapy in systemic
cancer. However, their infrequent and unreliable detection, especially in nonmetastatic …
cancer. However, their infrequent and unreliable detection, especially in nonmetastatic …
[HTML][HTML] An African American paternal lineage adds an extremely ancient root to the human Y chromosome phylogenetic tree
FL Mendez, T Krahn, B Schrack, AM Krahn… - The American Journal of …, 2013 - cell.com
We report the discovery of an African American Y chromosome that carries the ancestral
state of all SNPs that defined the basal portion of the Y chromosome phylogenetic tree. We …
state of all SNPs that defined the basal portion of the Y chromosome phylogenetic tree. We …
Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells
…, N Brychta, O von Ahsen, C Schumann, T Krahn… - Clinical Cancer …, 2016 - AACR
… The resulting regression revealed that none of the clinical factors (T, N, or M stage as well
as … T. Krahn is a consultant/advisory board member for Gilupi UK. K. Pantel is a consultant/…
as … T. Krahn is a consultant/advisory board member for Gilupi UK. K. Pantel is a consultant/…
Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices
…, B Bohms, A Kassner, R Körfer, M Klein, T Krahn… - The Journal of heart and …, 2008 - Elsevier
BACKGROUND: In this study we analyzed putative biomarkers for myocardial remodeling in
plasma from 55 endstage heart failure patients with the need for mechanical circulatory …
plasma from 55 endstage heart failure patients with the need for mechanical circulatory …
[HTML][HTML] Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders
…, W Nickl, T Krahn, P Ellinghaus, T Scheffold… - Cardiovascular …, 2009 - Springer
Background Diabetes mellitus (DM) has reached epidemic proportions and is an important
risk factor for heart failure (HF). Left ventricular diastolic dysfunction (LVDD) is recognized as …
risk factor for heart failure (HF). Left ventricular diastolic dysfunction (LVDD) is recognized as …